To test this, we generated iPSC lines homozygous for the AD non‐risk (CR1*1/CR1*1) and risk (CR1*2/CR1*2) variants, differentiated these into microglia and astrocytes, confirmed and quantified CR1 variant expression and tested phagocytic capacity for different cargos with or without cargo opsonization. This evidence concerns the gene CR1 and Alzheimer disease.